share_log

ChromaDex Announced Partnership With MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen and Tru Niagen PRO Into Brazil

Benzinga Real-time News ·  Sep 1, 2022 06:34

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen and Tru Niagen PRO in Brazil, the first Latin American country to welcome the brand. Nicotinamide riboside or NR, the key ingredient in Tru Niagen, is the world's most efficient nicotinamide adenine dinucleotide (NAD+) precursor on the market, particularly over NMN (nicotinamide mononucleotide). MyPharma2Go, an American company focused on Brazil and Latin America, developed a cross-border e-commerce platform that allows patients to have direct access to international medicines and supplements, and monitors the international shipping process from origin to delivery. Tru Niagen is one of Amazon's (U.S.) top-selling brands in the Vitamin B3 category for boosting NAD+ levels and features ChromaDex's proprietary ingredient, Niagen (patented nicotinamide riboside or NR). The cross-border distribution strategy allows for Tru Niagen 300mg 30 count bottles, Tru Niagen 300mg 90 count bottles and Tru Niagen 300mg 30 count Stickpacks to be purchased by consumers looking to age healthier. Additionally, MyPharma2Go is working with Brazilian Health Care Professionals (HCPs) to distribute Tru Niagen PRO bottles, which feature 500mg of Niagen, the highest single capsule dose currently on the market, to patients across the country. Supplementation with Niagen is backed by 20 published and peer-reviewed clinical studies, many of which involve daily doses of 1000mg or more of Niagen. Niagen has achieved regulatory acceptance for use in supplements by the US FDA. Niagen has also been approved for use in food supplements by the European Commission, complementary medicines by the Therapeutic Goods Administration of Australia (TGA), and medical foods by the Food Standards Australia New Zealand (FSANZ). Tru Niagen has also been approved by Health Canada as a Natural Health Product. Additionally, ChromaDex continues to lead the industry in NAD+ research and recently announced that the ChromaDex External Research Program (CERPTM) reached over 250 material transfer agreements (MTAs) featuring Niagen and other proprietary ingredients

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment